Drug
Beinaglutide clinical trials
Also written GLP-1 (7-36) amide.
- studies test it
- 12
- open now
- 1
- in phase 3
- 1
- first study started
- 2005
Keep track of what changes. Save the beinaglutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2011 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 1
- Phase 4
- 2
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 9
Mannkind Corporation (2) · Xijing Hospital (1) · Papworth Hospital NHS Foundation Trust (1) · AstraZeneca (1) · Jeppe Skov (1) · University of Aarhus (1) · Beijing Hospital (1) · Johns Hopkins University (1)
Often tested with
Tested in the same studies.
Glucagon-like peptide 1 (7-36)amide (2) · Insulin Glargine (1) · Glyburide (1) · Metformin (1)
Studies
Open first, then newest update. How each study uses beinaglutide is read from its arms, and is right about nine times in ten.
Testing it · 12
- Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM PatientsRecruitingNot applicableBeijing HospitalNCT03987308Written as Beinaglutide
- The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.Status unknownPhase 4Second Xiangya Hospital of Central South UniversityNCT05005741Written as Beinaglutide
- Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes MellitusCompletedNot applicableXijing HospitalNCT03829891Written as Beinaglutide
- Effects of Benaglutide on Weight and Gut Microbiota in Obese PatientsStatus unknownPhase 3Xiangya Hospital of Central South UniversityNCT03986008Written as Benaglutide
- Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight ControlStatus unknownPhase 4The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT03593668Written as Benaglutide
- Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) SurgeryTerminatedPhase 2Johns Hopkins UniversityNCT00966654Written as GLP-1 (7-36) amide
- Cardioprotective Effects of GLP-1 and Their MechanismsCompletedPhase 1Papworth Hospital NHS Foundation TrustNCT02128022Written as GLP-1 (7-36) amide
- PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart FailureCompletedPhase 2AstraZenecaNCT00099580Written as AC2592
- A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes MellitusCompletedPhase 1Mannkind CorporationNCT00642538Written as MKC253 Inhalation Powder
- A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult MalesCompletedPhase 1Mannkind CorporationNCT00475371Written as MKC253 Inhalation Powder
- GLP-1: Acute Effects on Kidney Function in Healthy MenCompletedNot applicableJeppe SkovNCT01333163Written as Human GLP-1 (7-36) amide
- GLP-1 Infusion and Long-Time FastingCompletedNot applicableUniversity of AarhusNCT00285896Written as Glucagon-like-peptide-1 (7-36) amide
Codes
What other systems call beinaglutide · ClinicalTrials.gg INT003472
- UNII (FDA) 38I1O6L31DBEINAGLUTIDEOne source FDA
- NCI Thesaurus C166656BeinaglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 38I1O6L31D | BEINAGLUTIDE | One source FDA |
| NCI Thesaurus | C166656 | Beinaglutide | One source FDA |
Also registered as glucagon-like peptide-i(7-36) amide (UNII 0JS9125PIZ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.